Actively Recruiting
Assessment of Endometrial Thickness Among Adolescent and Young Adult Patients on Estrogen Replacement Therapy Using Continuous Oral Micronized Progesterone Versus the Etonogestrel Implant a Prospective Pilot Study
Led by University of Colorado, Denver · Updated on 2024-12-06
34
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
This research aims to compare the thickness of the endometrial lining in adolescent and young adult females on estrogen replacement therapy using two types of progesterone treatments daily oral micronized progesterone and the etonogestrel implant. The study focuses on patients aged 12 to 25 years with specific diagnoses requiring estrogen therapy, addressing gaps in knowledge about endometrial protection and bleeding patterns in this group. Participants will choose between two progesterone therapies oral micronized progesterone taken daily at 100mg or the etonogestrel implant placed in a clinic. The study will last six months, during which participants will continue their estrogen therapy and start their selected progesterone treatment. Two pelvic ultrasounds will be performed, one at the start and one after six months of progesterone use, to measure changes in endometrial thickness. Throughout the study, participants will complete surveys about bleeding patterns, side effects, satisfaction, and adherence to their progesterone treatment. The study team will track medication use through pill counts or photos for those on oral progesterone. All ultrasound and survey data will be securely stored and analyzed to assess the mean change in endometrial thickness and other patient-reported outcomes over six months.
CONDITIONS
Brief Title
Assessment of Endometrial Thickness Among Adolescent and Young Adult Patients on Estrogen Replacement Therapy Using Daily Oral Micronized Progesterone Versus the Etonogestrel Implant.
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 12-25 years at baseline
- Female assigned at birth, with uterus
- Diagnosis of primary ovarian insufficiency or hypogonadotropic hypogonadism, requiring estrogen replacement therapy
- Receiving estradiol therapy orally (1-2mg) or transdermally (0.05-0.1mg) for at least 3 months
- Never used progesterone therapy or stopped it at least 90 days prior to enrollment
- Willing to start progesterone therapy
You will not qualify if you...
- Uterine abnormalities such as M�fcllerian anomaly or uterine fibroids
- Unable to clearly measure the endometrial lining on ultrasound
- History of chemotherapy or radiation therapy
- Unable to complete study questionnaires
Research Team
J
Julie C Friedman, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here